Clinical Trial News and Research

RSS

New prognostic markers help identify risk of relapse

A recently completed clinical study has found new prognostic markers that may help clinicians identify those children with leukaemia who are at high risk of relapse and are most in need of intensified treatment to improve their chance of survival.

1 May 2005

Antibiotic minocycline might help alleviate HIV's negative effects on the brain and central nervous system

By studying animals, Johns Hopkins researchers have discovered that the antibiotic minocycline might help alleviate HIV's negative effects on the brain and central nervous system, problems that can develop even though antiretroviral therapy controls the virus elsewhere in the body.

1 May 2005

Australian clinical trial of potent new anticancer drug (CYT997)

Up to 30 patients with advanced incurable solid-tumours are to be involved in clinical trials of a potent new anticancer drug (CYT997), developed by Australian biotechnology company, Cytopia Limited.

27 Apr 2005

Antibiotics do not prevent heart attacks

Clinicians and researchers have found that more than three quarters of heart attack patients have been infected with chlamydia pneumoniae - a bacteria found in arteries of heart attack patients - and multiple studies have found this can double the risk of developing subsequent heart attacks.

27 Apr 2005

Moderate hypothermia is a safe treatment following traumatic brain injury in children

A first-of-its-kind multi-center trial has shown that cooling the body can have positive affects on children who suffered traumatic brain injury.

27 Apr 2005

New clinical trial focuses on quality of life for men with prostate cancer

A new Australian prostate cancer clinical trial hopes to provide clear evidence to men with prostate cancer about the best time to start hormone treatment in terms of prolonging life, balanced against the effects on their quality of life.

27 Apr 2005

National clinical trial examines new option for kidney cancer patients

The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.

27 Apr 2005

GenoMed launches free trial against Marburg virus epidemic in Angola

GenoMed announced today that it has launched a free clinical trial to combat the current Marburg virus epidemic in Angola.

26 Apr 2005

Gene therapy for Alzheimer's disease shows promise

In the first clinical trial of gene therapy for Alzheimer's disease researchers have produced preliminary evidence that gene therapy may slow the decline in mental functioning associated with Alzheimer's disease.

25 Apr 2005

Substantially more effective therapy than current treatments for Alzheimer's disease

PET scans and cognitive tests have suggested that Alzheimer's disease patients with genetically modified tissue inserted directly into their brains show a reduction in the rate of cognitive decline and increased metabolic activity in the brain, according to a study published in the April 24, 2005 online issue of the journal Nature Medicine by researchers at the University of California, San Diego (UCSD) School of Medicine.

25 Apr 2005

Elderly lung cancer patients tolerate combined chemotherapy and radiotherapy with no higher risk of death than younger patients

Lung cancer remains the leading cause of cancer deaths in the U.S., with half of those diagnosed at age 70 years or older. About 20 percent of patients with lung cancer will have small cell lung cancer (SCLC). In the past, SCLC progressed rapidly despite initial chemotherapy sensitivity and few patients survive three years.

25 Apr 2005

Increasing benefit seen in novel drug AMN107, that treats Gleevec resistance

An investigational drug is producing powerful responses in patients resistant to Gleevec, the targeted therapy that helps most people diagnosed with chronic myeloid leukemia (CML), an international research team headed by investigators at The University of Texas M. D. Anderson Cancer Center is reporting.

23 Apr 2005

Clinical study of MDX-010/MDX-1379 combination shows durable responses in patients with metastatic melanoma

Medarex, Inc. and Bristol-Myers Squibb Company announced today that complete or partial responses in seven of 56 patients with metastatic melanoma showed durability ranging from four months to the longest still ongoing at over 34 months, with five of the seven responses ongoing for more than two years.

20 Apr 2005

Fast Track designation for Terlipressin in type 1 hepatorenal syndrome

Protein Design Labs, Inc. and privately held Orphan Therapeutics, LLC today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to the development of terlipressin for the treatment of patients with type 1 hepatorenal syndrome (HRS).

20 Apr 2005

FDA expert panel to review Abiomed's artificial heart

Abiomed, Inc. today announced that the U.S. Food and Drug Administration (FDA) will convene an expert panel of cardiovascular surgeons and cardiologists to review the groundbreaking technologies and clinical trial data behind the AbioCor artificial heart.

20 Apr 2005

Green tea appears to prevent cancer in men

After a year's oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D.

20 Apr 2005

Breast cancer gene may play a major role in the recurrence of prostate cancer

A gene associated with breast cancer also may play a major role in the recurrence of prostate cancer, according to new research from the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center.

20 Apr 2005

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

Researchers at Fox Chase Cancer Center in Philadelphia have identified a subset of ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa. The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, Calif.

20 Apr 2005

New method for obtaining sequence information from thousands of genomes simultaneously

One of the world’s leading scientists, Nobel Prize winner, Dr Sydney Brenner, has devised a new method for obtaining sequence information from thousands of genomes simultaneously. Current technologies can only analyse one genome at a time.

20 Apr 2005

New era drug gives hope to Gleevec resistant leukaemia sufferers

Gleevec, a drug regarded by many as having "wonder drug" capabilities in the treatment of chronic myelogenous leukaemia (CML) and other cancers, has been revealed as having shortcomings in that some patients have undergone a relapse after building a resistance to the drug. For others with the advanced stage of the disease, the drug has failed to produce durable remissions.

19 Apr 2005

Clinical Trial News and Research

New prognostic markers help identify risk of relapse

Antibiotic minocycline might help alleviate HIV's negative effects on the brain and central nervous system

Australian clinical trial of potent new anticancer drug (CYT997)

Antibiotics do not prevent heart attacks

Moderate hypothermia is a safe treatment following traumatic brain injury in children

New clinical trial focuses on quality of life for men with prostate cancer

National clinical trial examines new option for kidney cancer patients

GenoMed launches free trial against Marburg virus epidemic in Angola

Gene therapy for Alzheimer's disease shows promise

Substantially more effective therapy than current treatments for Alzheimer's disease

Elderly lung cancer patients tolerate combined chemotherapy and radiotherapy with no higher risk of death than younger patients

Increasing benefit seen in novel drug AMN107, that treats Gleevec resistance

Clinical study of MDX-010/MDX-1379 combination shows durable responses in patients with metastatic melanoma

Fast Track designation for Terlipressin in type 1 hepatorenal syndrome

FDA expert panel to review Abiomed's artificial heart

Green tea appears to prevent cancer in men

Breast cancer gene may play a major role in the recurrence of prostate cancer

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

New method for obtaining sequence information from thousands of genomes simultaneously

New era drug gives hope to Gleevec resistant leukaemia sufferers

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Metabolomics

Improve fermentation and cell culture performance with real-time gas analysis

Scaling patient-derived organoid research

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer